Pharmacy Plus, Inc. dba Vital Care Compounder
Has Pharmacy Plus, Inc. dba Vital Care Compounder received an FDA warning letter about GLP-1 drugs?
No FDA warning letter to Pharmacy Plus, Inc. dba Vital Care Compounder naming a GLP-1 drug appears in FDA’s posted letters as of Nov 15, 2026. The company is listed here because openFDA has 2 drug recall reports for it naming semaglutide, the latest initiated Apr 13, 2023.
FDA records in this index name Pharmacy Plus, Inc. dba Vital Care Compounder from Oct 7, 2022 to Apr 13, 2023.
- Type named in FDA records
- Not stated
- FDA warning letters
- 0
- Drug recall reports
- 2
- Drugs named
- Semaglutide
- Latest record
- Apr 13, 2023
FDA warning letters
No FDA warning letters in this index.
Drug recalls
| Record | |||||
|---|---|---|---|---|---|
| Apr 13, 2023 | C-Semaglutide 5mg/mL injection, 0.5mL vials, Rx only, Vital Care Compounder 115 South 40th Ave, Suite A Hattiesburg, MS 39402 | Lack of assurance of sterility. | Class II | Ongoing | D-0538-2023 |
| Oct 7, 2022 | SEMAGLUTIDE INJECTION 5MG/ML (0.25MG/0.05ML) SOLN, various amounts in unit dose vials, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402 | Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility ... | Class II | Ongoing | D-0053-2023 |
FDA compounding inspections and actions
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists one facility under this exact legal name. These entries cover all of the facility’s compounding, not only GLP-1 drugs.
Pharmacy Plus, Inc. (dba Vital Care Compounder LLC), Hattiesburg, MS (503A)
3 listed actions, including 2 Form 483s and 1 warning letter (2019 to 2023).
| Document | |||
|---|---|---|---|
| Jun 6, 2023 | Warning letter | Warning Letter (06/06/2023) | FDA copy (archived) |
| Oct 13, 2022 | Form 483 | 483 Issued 10/13/2022 | FDA copy (archived) |
| May 16, 2019 | Form 483 | 483 Issued 05/16/2019 | fda.gov |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.
Pharmacy pages with the same legal name, built from FDA’s 503B list and compounding inspections and actions page: Vital Care Compounder LLC (Pharmacy Plus, Inc.), Hattiesburg, MS.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- openFDA drug recall enforcement reports
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA warning letters (fda.gov full-text search)
Records last pulled Nov 15, 2026. Every entry links to the original public record.